STAAR Surgical Company reports developments in lens-based refractive surgery through its EVO family of Implantable Collamer® Lenses, including EVO ICL™ for vision correction. The company designs, manufactures and sells implantable lenses for the eye and related delivery systems, with ICL products forming the core of its revenue base.
Recurring updates cover quarterly and annual results, preliminary sales, strategic-plan progress, market trends in China, the Americas and other international markets, regulatory indication changes, clinical evidence for EVO ICL, product adoption milestones, board and executive transitions, and shareholder voting or governance matters.
STAAR Surgical (NASDAQ: STAA) will release first quarter 2026 financial results for the period ended April 3, 2026, on Wednesday, May 13, 2026, after market close and host an earnings call and webcast at 5:30 p.m. ET.
Management will discuss first quarter results, strategic priorities, revenue and profit trends, innovation progress, and market dynamics including China. The live webcast is available with preregistration and a replay will be accessible for at least 90 days.
STAAR is a manufacturer of EVO ICL implantable lenses, with more than 4 million ICLs sold in over 85 countries, headquartered in Lake Forest, California.
STAAR Surgical (NASDAQ: STAA) said preliminary Q1 2026 net sales exceeded $90 million, versus $42.6 million in Q1 2025. Management cited strong China sales and double‑digit growth in the Americas, plus a significantly improved cost structure expected to boost adjusted EBITDA.
The results are unaudited, subject to adjustment, and the company reiterated it will not provide forward revenue or earnings guidance.
STAAR Surgical (NASDAQ: STAA) issued a March 3, 2026 shareholder letter outlining a reset after a difficult 2025 and a plan to drive revenue growth, profit expansion, and faster innovation in 2026.
The company cites China inventory normalization, Swiss manufacturing ramp, cost reductions beating a $225M second‑half run rate target, EVO+ China approval and shipments, and FDA age expansion for EVO ICL as key catalysts.
STAAR Surgical (NASDAQ: STAA) reported Q4 2025 net sales of $57.8M (+18.1% Y/Y) and fiscal 2025 net sales of $239.4M (-23.7% Y/Y). Gross margin improved to 75.7% Q4; Adjusted EBITDA was breakeven in Q4 versus a prior loss. Cash and investments totaled $187.5M, with no debt and ongoing share repurchase capacity.
The company cites China inventory normalization and EVO+ ICL launch as drivers for expected 2026 growth and announced interim co-CEOs and an external CEO search.
STAAR Surgical (NASDAQ: STAA) announced it has surpassed 4 million Implantable Collamer Lenses (ICLs) sold worldwide, marking accelerating adoption of lens-based refractive correction over laser-based procedures. The company cited expanded regulatory indications, growing real-world evidence, and long-term clinical outcomes as drivers of broader patient access.
STAAR reported ICLs implanted since 1993, sales milestones at 1M (2019), 2M (2022), 3M (2024), and noted sales in over 85 countries with an average ICL patient age of 32 (2025).
STAAR Surgical (NASDAQ: STAA) will release fourth quarter and fiscal year 2025 financial results on March 3, 2026 after market close and host an earnings call and webcast at 5:30 p.m. ET.
Topics include fiscal 2025 operations, China recovery, inventory normalization, cost discipline, Switzerland manufacturing expansion, innovation pipeline, and 2026 strategic focus. A replay will be available for at least 90 days.
STAAR Surgical (NASDAQ: STAA) announced the FDA expanded the U.S. age indication for EVO/EVO+ Visian ICL to 21–60 years, widening the addressable market by nearly 8 million U.S. adults. The decision follows three-year FDA trial data (629 eyes) showing a safety index of 1.25 and a 0.16% anterior subcapsular cataract incidence. Market data cited a ~40% decline in laser corneal procedures over three years and that EVO ICL accounted for 72% of procedures in patients with ≤-8.0 D, signaling a shift toward lens-based correction.
STAAR Surgical (NASDAQ: STAA) appointed Warren Foust, President and COO, and Deborah Andrews, CFO, as interim co‑CEOs, effective February 1, 2026.
The Board said both will lead day‑to‑day operations while a Board‑appointed Search Committee has initiated a global search for a permanent CEO, engaging executive search firms and evaluating internal and external candidates.
STAAR Surgical (NASDAQ: STAA) and activist investor Broadwood Partners entered a cooperation agreement effective January 15, 2026, after Broadwood disclosed ownership of 31% of STAAR and Yunqi Capital disclosed 6.5%. Broadwood principals Neal C. Bradsher and Richard T. LeBuhn and Christopher Wang of Yunqi joined STAAR's Board immediately, expanding the Board from six to seven members. Chair Elizabeth Yeu and Director-Board member CEO Stephen Farrell stepped down from the Board; Farrell will remain CEO until January 31, 2026. The company said the Board will announce a new Chair and CEO in the near term and will file the Cooperation Agreement as an exhibit to a Form 8-K.
Alcon (SIX/NYSE: ALC) announced on January 7, 2026 that it has terminated its definitive merger agreement to acquire STAAR Surgical (NASDAQ: STAA) that was announced on August 5, 2025. The company said it remained disciplined on price and risk and that its refractive strategy is unchanged, with a continued focus on its wavelight® plus offering for LASIK.
Alcon also said it will continue global launches of more than 10 major products across surgical and vision care this year and reiterated forward-looking caution about uncertainties and risks.